The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 18, 2025

Filed:

Apr. 21, 2022
Applicants:

Astellas Pharma Inc., Tokyo, JP;

National Cancer Center, Tokyo, JP;

Inventors:

Yoshiyuki Tenda, Tokyo, JP;

Masatoshi Yuri, Tokyo, JP;

Shigenori Yagi, Tokyo, JP;

Yoshiki Satake, Tokyo, JP;

Kazunori Hirayama, Tokyo, JP;

Hiroki Shirai, Tokyo, JP;

Hiroki Sasaki, Tokyo, JP;

Fumiko Chiwaki, Tokyo, JP;

Masayuki Komatsu, Tokyo, JP;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2878 (2013.01); A61P 35/00 (2018.01); C07K 16/28 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01);
Abstract

An object of the present invention is to provide an anti-CLDN4/anti-CD137 bispecific antibody usable in treatment of cancer. An anti-CLDN4/anti-CD137 bispecific antibody produced using an anti-CLDN4 antibody binding to CLDN4 and an anti-CD137 antibody binding to CD137 had agonistic activity for CD137, promoted production of interferon γ by a T cell, and exhibited cytotoxic activity against a cancer cell expressing CLDN4 on a cell surface thereof. Besides, it was shown that the anti-CLDN4/anti-CD137 bispecific antibody can be safely administered to monkeys. Therefore, the anti-CLDN4/anti-CD137 bispecific antibody is usable in treatment of human cancer.


Find Patent Forward Citations

Loading…